Qlaris Bio appointed Fred Guerard, PharmD, as its president and CEO, according to a press release.The company is entering phase 3 development of QLS-111, a novel eye drop for lowering IOP in patients with open-angle glaucoma and ocular hypertension (OH…
Click here to read the Point/Counter to this Cover Story.The introduction of the first disease-modifying therapies fundamentally transformed the management of geographic atrophy and brought new changes and challenges in clinical practice, workflow and …
Polygenic risk scores in development for glaucoma could usher in more personalized estimates of risk. Medscape Medical News
Editor’s note: This is a developing news story. Please check back soon for updates.At 12 months in a phase 1/2 trial, the Bimatoprost Drug Pad-IOL System improved IOP, vision and treatment burden in patients with open-angle glaucoma or ocular hypertens…
A new clinical delivery model offers resources to help health care providers, or HCPs, become more culturally competent and improve health outcomes for their Black patients, an expert said.BlackDoctor is a “leading health and wellness destination for B…
In this video from the Macula Society meeting, Theodore Leng, MD, FACS, discusses MCO-010, an optogenetic therapy from Nanoscope Therapeutics under study for advanced retinitis pigmentosa and geographic atrophy.“This program is actually planning to lau…